Mineralys Stock

mineralystx.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $159.18MM

Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone levels. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys is initially developing for the treatment of patients with uncontrolled hypertension. The company has plans for the continued research and development of lorundrostat in hypertension and other potential indications. Mineralys Therapeutics was founded in 2019, and is headquartered in Radnor, Pennsylvania.

Register for Details

For more details on financing and valuation for Mineralys, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Mineralys.

Register Today

Team

Management Team

Jon Congleton
Chief Executive Officer
David Rodman, MD
Chief Medical Officer
Adam Levy
Chief Financial Officer & Chief Business Officer

Board Members

Olivier Litzka, PhD
Andera Partners
Derek DiRocco, PhD
RA Capital Management
Takeshi Takahashi
Catalys Pacific

Other companies like Mineralys in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Mineralys Therapeutics sets IPO target at up to $160M
The Main Line biopharmaceutical company stated in documents filed with the SEC that it plans to sell 10 million shares of common stock.
Updated on: Sep 22, 2023